184 related articles for article (PubMed ID: 8822422)
1. Efficacy and safety of recombinant follicle stimulating hormone (Puregon) in infertile women pituitary-suppressed with triptorelin undergoing in-vitro fertilization: a prospective, randomized, assessor-blind, multicentre trial.
Hedon B; Out HJ; Hugues JN; Camier B; Cohen J; Lopes P; Zorn JR; van der Heijden B; Coelingh Bennink HJ
Hum Reprod; 1995 Dec; 10(12):3102-6. PubMed ID: 8822422
[TBL] [Abstract][Full Text] [Related]
2. A prospective, randomized, assessor-blind, multicentre study comparing recombinant and urinary follicle stimulating hormone (Puregon versus Metrodin) in in-vitro fertilization.
Out HJ; Mannaerts BM; Driessen SG; Bennink HJ
Hum Reprod; 1995 Oct; 10(10):2534-40. PubMed ID: 8567765
[TBL] [Abstract][Full Text] [Related]
3. A double-blind, randomized study to compare recombinant human follicle stimulating hormone (FSH; Gonal-F) with highly purified urinary FSH (Metrodin) HP) in women undergoing assisted reproductive techniques including intracytoplasmic sperm injection. The French Multicentre Trialists.
Frydman R; Howles CM; Truong F
Hum Reprod; 2000 Mar; 15(3):520-5. PubMed ID: 10686190
[TBL] [Abstract][Full Text] [Related]
4. [Effect of domestic highly purified urinary follicle stimulating hormone on outcomes of in vitro fertilization-embryo transfer in controlled ovarian stimulation].
Ye H; Huang GN; Cao YX; Zhong Y; Huang YH; Zhu GJ; Zhou LM; Chen ZJ; Shi JZ; Zeng Y; Weng N; Huang XF; Yang J; Zhu YM; Li YP; Yi D; Zhuang GL
Zhonghua Fu Chan Ke Za Zhi; 2013 Nov; 48(11):838-42. PubMed ID: 24444561
[TBL] [Abstract][Full Text] [Related]
5. Superovulation before IVF by recombinant versus urinary human FSH (combined with a long GnRH analog protocol): a comparative study.
Fisch B; Avrech OM; Pinkas H; Neri A; Rufas O; Ovadia J; Loumaye E
J Assist Reprod Genet; 1995 Jan; 12(1):26-31. PubMed ID: 7580006
[TBL] [Abstract][Full Text] [Related]
6. Ovarian stimulation in women undergoing in-vitro fertilization and embryo transfer using recombinant human follicle stimulating hormone (Gonal-F) in non-down-regulated cycles.
Strowitzki T; Kentenich H; Kiesel L; Neulen J; Bilger W
Hum Reprod; 1995 Dec; 10(12):3097-101. PubMed ID: 8822421
[TBL] [Abstract][Full Text] [Related]
7. Oestradiol and immunoreactive inhibin-like secretory patterns following controlled ovarian hyperstimulation with urinary (Metrodin) or recombinant follicle stimulating hormone (Puregon).
Mitchell R; Buckler HM; Matson P; Lieberman B; Burger HG; Hilton B; Horne G; Dyson M; Robertson WR
Hum Reprod; 1996 May; 11(5):962-7. PubMed ID: 8671371
[TBL] [Abstract][Full Text] [Related]
8. Comparison of two recombinant follicle-stimulating hormone preparations in in-vitro fertilization: a randomized clinical study.
Tulppala M; Aho M; Tuuri T; Vilska S; Foudila T; Hakala-Ala-Pietilä T; Moilanen J; Bützow T; Kaukoranta S; Söderström-Anttila V; Siegberg R; Suikkari AM; Hovatta O
Hum Reprod; 1999 Nov; 14(11):2709-15. PubMed ID: 10548606
[TBL] [Abstract][Full Text] [Related]
9. A prospective, randomized clinical trial comparing 150 IU recombinant follicle stimulating hormone (Puregon((R))) and 225 IU highly purified urinary follicle stimulating hormone (Metrodin-HP((R))) in a fixed-dose regimen in women undergoing ovarian stimulation.
Hoomans EH; Andersen AN; Loft A; Leerentveld RA; van Kamp AA; Zech H
Hum Reprod; 1999 Oct; 14(10):2442-7. PubMed ID: 10527965
[TBL] [Abstract][Full Text] [Related]
10. A prospective, randomized, double-blind clinical trial to study the efficacy and efficiency of a fixed dose of recombinant follicle stimulating hormone (Puregon) in women undergoing ovarian stimulation.
Out HJ; Lindenberg S; Mikkelsen AL; Eldar-Geva T; Healy DL; Leader A; Rodriguez-Escudero FJ; Garcia-Velasco JA; Pellicer A
Hum Reprod; 1999 Mar; 14(3):622-7. PubMed ID: 10221686
[TBL] [Abstract][Full Text] [Related]
11. Efficacy of recombinant human follicle-stimulating hormone in improving oocyte quality in assisted reproductive techniques.
Cheon KW; Byun HK; Yang KM; Song IO; Choi KH; Yoo KJ
J Reprod Med; 2004 Sep; 49(9):733-8. PubMed ID: 15493565
[TBL] [Abstract][Full Text] [Related]
12. A group-comparative, randomized, double-blind comparison of the efficacy and efficiency of two fixed daily dose regimens (100- and 200-IU) of recombinant follicle stimulating hormone (rFSH, Puregon) in Asian women undergoing ovarian stimulation for IVF/ICSI.
Hoomans EH; Mulder BB;
J Assist Reprod Genet; 2002 Oct; 19(10):470-6. PubMed ID: 12416651
[TBL] [Abstract][Full Text] [Related]
13. Recombinant follicle-stimulating hormone (FSH; Puregon) is more efficient than urinary FSH (Metrodin) in women with clomiphene citrate-resistant, normogonadotropic, chronic anovulation: a prospective, multicenter, assessor-blind, randomized, clinical trial. European Puregon Collaborative Anovulation Study Group.
Coelingh Bennink HJ; Fauser BC; Out HJ
Fertil Steril; 1998 Jan; 69(1):19-25. PubMed ID: 9457926
[TBL] [Abstract][Full Text] [Related]
14. A randomized, assessor-blind, group-comparative efficacy study to compare the effects of Normegon and Metrodin in infertile female patients undergoing in-vitro fertilization.
Devroey P; Tjandraprawira K; Mannaerts B; Coelingh Bennink H; Smitz J; Bonduelle M; De Brabanter A; Van Steirteghem AC
Hum Reprod; 1995 Feb; 10(2):332-7. PubMed ID: 7769058
[TBL] [Abstract][Full Text] [Related]
15. Recombinant human follicle stimulating hormone (r-hFSH; Gonal-F) versus highly purified urinary FSH (Metrodin HP): results of a randomized comparative study in women undergoing assisted reproductive techniques.
Bergh C; Howles CM; Borg K; Hamberger L; Josefsson B; Nilsson L; Wikland M
Hum Reprod; 1997 Oct; 12(10):2133-9. PubMed ID: 9402268
[TBL] [Abstract][Full Text] [Related]
16. Prospective, randomized study comparing highly purified urinary follicle-stimulating hormone (FSH) and recombinant FSH for in vitro fertilization/intracytoplasmic sperm injection in patients with polycystic ovary syndrome.
Aboulghar M; Saber W; Amin Y; Aboulghar M; Mansour R; Serour G
Fertil Steril; 2010 Nov; 94(6):2332-4. PubMed ID: 20188364
[TBL] [Abstract][Full Text] [Related]
17. Recombinant follicle-stimulating hormone and recombinant luteinizing hormone versus recombinant follicle-stimulating hormone alone during GnRH antagonist ovarian stimulation in patients aged ≥35 years: a randomized controlled trial.
Vuong TN; Phung HT; Ho MT
Hum Reprod; 2015 May; 30(5):1188-95. PubMed ID: 25740882
[TBL] [Abstract][Full Text] [Related]
18. A double-blind, randomized, dose-finding study to assess the efficacy of the gonadotrophin-releasing hormone antagonist ganirelix (Org 37462) to prevent premature luteinizing hormone surges in women undergoing ovarian stimulation with recombinant follicle stimulating hormone (Puregon). The ganirelix dose-finding study group.
Hum Reprod; 1998 Nov; 13(11):3023-31. PubMed ID: 9853849
[TBL] [Abstract][Full Text] [Related]
19. Safety and efficacy of Ovaleap® (recombinant human follicle-stimulating hormone) for up to 3 cycles in infertile women using assisted reproductive technology: a phase 3 open-label follow-up to Main Study.
Strowitzki T; Kuczynski W; Mueller A; Bias P
Reprod Biol Endocrinol; 2016 Jun; 14(1):31. PubMed ID: 27287439
[TBL] [Abstract][Full Text] [Related]
20. Corifollitropin alfa followed by highly purified HMG versus recombinant FSH in young poor ovarian responders: a multicentre randomized controlled clinical trial.
Drakopoulos P; Vuong TNL; Ho NAV; Vaiarelli A; Ho MT; Blockeel C; Camus M; Lam AT; van de Vijver A; Humaidan P; Tournaye H; Polyzos NP
Hum Reprod; 2017 Nov; 32(11):2225-2233. PubMed ID: 29040589
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
